Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC) -- Ignore unavailable to you. Want to Upgrade?

To: IRWIN JAMES FRANKEL who wrote (602)	3/14/2005 10:33:11 PM
From: Extra Pale	Respond to of 946

Agree no comparison between ctic & dna. What I find interesting is the huge mkt cap gain for dna of over $10billion. Seems to me the market is getting way ahead, ala elan, biib. Also, does indicate the risk reward for ctic was very favorable, IMO, from a gambling perspective. May be a 20% chance of xyotax being approved - but overall expected value is grand. Have come to realize that nearly all biotechs are venture capital deals, high risk high loss, and occasionally a nice payday.

To: IRWIN JAMES FRANKEL who wrote (602)	3/15/2005 11:15:09 AM
From: Sam Citron	Read Replies (1) \| Respond to of 946

Brief description of Avastin success from SSB: This afternoon, the NIH (National Institutes of Health) announced the positive outcome of a large clinical study of Avastin in advanced lung cancer known as ECOG 4599 earlier than anticipated. Genentech's stock was up nearly 25% (+$10.92) in reaction to this news. The study was designed to assess Avastin in combination with standard chemotherapy (i.e., carboplatin/paclitaxel) as a first-line treatment in advanced non-small cell lung cancer (NSCLC) with a primary end point of overall survival. Since patient enrollment was completed in early 2004 and the study was event-driven basedon the number of deaths, the results were anticipated in either late Q2 or in the second half of 2005 assuming the comparative control arm achieved a median overall survival level of 8-11 months. Specifically, the results from a recent interim analysis, which led to this announcement, indicate an overall survival benefit in patients receiving Avastin in combination with standard chemotherapy. Patients in this arm of the study achieved a median overall survival of 12.5 months compared to 10.2 months in patients receiving standard chemotherapy alone. This difference of 2.3 months is statistically significant and led the NIH to release these top-line results earlier than expected since the study had met the primary endpoint. This early release of the data will allow presentation of the detailed results in time for the annual American Society of Clinical Oncology (ASCO) annual meeting to be held in Orlando, Florida, on May 13-17, 2005. In our opinion, the opportunity for Avastin as a front-line therapy in advanced lung cancer represents an additional $1+ billion market. This reinforces our belief that Avastin may represent a multi-billion dollar opportunity. I would think there are strong competitive implications since ECOG 4599 had similar design to Stellar 3 but was able to demonstrate significant survival benefit. I am no biomaven however, so would appreciate any comments/criticisms, in order to get a better understanding. Might Avastin success even hurt Xyotax's chances for approval? Sam